These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 2930705)

  • 1. The size of clinical trials in cancer research--what are the current needs? Medical Research Council Cancer Therapy Committee.
    Freedman LS
    Br J Cancer; 1989 Mar; 59(3):396-400. PubMed ID: 2930705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring clinical trials: experience of, and proposals under consideration by, the Cancer Therapy Committee of the British Medical Research Council.
    Parmar MK; Machin D
    Stat Med; 1993 Mar; 12(5-6):497-504. PubMed ID: 8493427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer treatment trials--past failures, current progress and future prospects.
    Peto J; Easton D
    Cancer Surv; 1989; 8(3):511-33. PubMed ID: 2701083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The project data sphere initiative: accelerating cancer research by sharing data.
    Green AK; Reeder-Hayes KE; Corty RW; Basch E; Milowsky MI; Dusetzina SB; Bennett AV; Wood WA
    Oncologist; 2015 May; 20(5):464-e20. PubMed ID: 25876994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efaproxiral: GSJ 61, JP 4, KDD 86, RS 4, RSR 13.
    Drugs R D; 2005; 6(3):178-85. PubMed ID: 15869322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium.
    Drugs R D; 2007; 8(5):321-34. PubMed ID: 17767397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Globalization of clinical trials].
    Akaza H; Fukuoka M; Ohtsu A; Usami M; Ikeda T; Aiba K; Isonishi S; Ohashi Y; Saijo N; Sone S; Tsukagoshi S; Tsuruo T; Kato M; Mikami O; Dong RP; von Euler M; Blackledge G; Stribling D
    Gan To Kagaku Ryoho; 2003 Apr; 30(4):555-65. PubMed ID: 12722692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
    Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
    Adis International Ltd
    Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.
    Vogelzang NJ; Benowitz SI; Adams S; Aghajanian C; Chang SM; Dreyer ZE; Janne PA; Ko AH; Masters GA; Odenike O; Patel JD; Roth BJ; Samlowski WE; Seidman AD; Tap WD; Temel JS; Von Roenn JH; Kris MG
    J Clin Oncol; 2012 Jan; 30(1):88-109. PubMed ID: 22147736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. INGN 201: Ad-p53, Ad5CMV-p53, Adenoviral p53, INGN 101, p53 gene therapy--Introgen, RPR/INGN 201.
    BioDrugs; 2003; 17(3):216-22. PubMed ID: 12749760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update in methodology and conduct of cancer clinical trials.
    Therasse P; Eisenhauer EA; Buyse M
    Eur J Cancer; 2006 Jul; 42(10):1322-30. PubMed ID: 16737813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cancer and leukemia group B cancer in the elderly committee: addressing a major cancer need.
    Cohen HJ; Muss HB
    Clin Cancer Res; 2006 Jun; 12(11 Pt 2):3606s-11s. PubMed ID: 16740793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design.
    Peto R; Pike MC; Armitage P; Breslow NE; Cox DR; Howard SV; Mantel N; McPherson K; Peto J; Smith PG
    Br J Cancer; 1976 Dec; 34(6):585-612. PubMed ID: 795448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving enrollment in clinical trials for adolescents with cancer.
    Shaw PH; Hayes-Lattin B; Johnson R; Bleyer A
    Pediatrics; 2014 Jun; 133 Suppl 3():S109-13. PubMed ID: 24918208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient advocates' role in clinical trials: perspectives from Cancer and Leukemia Group B investigators and advocates.
    Katz ML; Archer LE; Peppercorn JM; Kereakoglow S; Collyar DE; Burstein HJ; Schilsky RL; Partridge AH
    Cancer; 2012 Oct; 118(19):4801-5. PubMed ID: 22392584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends in clinical trials reports in common cancers between 1989 and 2000.
    Hillner BE
    J Clin Oncol; 2003 May; 21(9):1850-8. PubMed ID: 12721263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multistage designs for phase II clinical trials: statistical issues in cancer research.
    Kramar A; Potvin D; Hill C
    Br J Cancer; 1996 Oct; 74(8):1317-20. PubMed ID: 8883425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Applying results of randomised trials to clinical practice: impact of losses before randomisation.
    Charlson ME; Horwitz RI
    Br Med J (Clin Res Ed); 1984 Nov; 289(6454):1281-4. PubMed ID: 6437520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.